Press Release
20 November 2026 11:07:00 CET

NANOLOGICA CHANGES DATES FOR INTERIM REPORT

Nanologica's interim report for the third quarter will be published on November 30 instead of November 26.

Due to recently implemented organizational changes, the company's interim report for Q3 2026 is postponed to November 30 instead of November 26 as previously communicated. The report will be published on the company's website around 08:10.

For further information, please contact
Johanna Westerberg
Director IR, Communications and Marketing
johanna.westerberg@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)
Nanologica is a Swedish life science group that offers advanced solutions for the development, manufacture and purification of pharmaceuticals. By combining expertise in materials science, nanotechnology and chemical process development with contract development and manufacturing services, Nanologica supports the value chain from early development to commercial production of pharmaceuticals. The Group has particular strength in complex molecules and peptide-based drugs. The Group has appx. 70 employees and is headquartered in Södertälje, Sweden. Nanologica's share (ticker: NICA) has been listed on Nasdaq Stockholm's main market since 2022. For more information, please visit www.nanologica.com.

Attachments
NANOLOGICA CHANGES DATES FOR INTERIM REPORT